Navigation Links
BioMedical Enterprises, Inc. (BME) Receives FDA Clearance for Spine Use of Its Memory Metal Implants
Date:10/22/2007

SAN ANTONIO, Oct. 22 /PRNewswire/ -- BioMedical Enterprises, Inc. (BME), a privately held medical device company and leader in orthopedic shape memory implant technology, today announced that the U.S. Food and Drug Administration (FDA) has given 510(k) marketing clearance to the OSSpine(TM) for use in anterior fixation of the cervical spine to provide enhanced biomechanical stability & bone graft retention. The patent-pending OSSpine(TM) builds on the extremity bone fusion success of BME's OSStaple(TM) and OSSplate(TM), and joins the Step OSStaple(TM) and the OSSArc(TM) dynamic residual compression implants as the most recent additions to BME's OSSforce(TM) Fixation System.

Made of nitinol, a biocompatible alloy possessing shape memory and super-elastic properties, the OSSpine(TM) implant is inserted while in its malleable state at room temperature. Using BME's patent-pending OSSforce(TM) Implant Controller, the implant is safely heated to activate its shape change and impart compression forces across the fusion site. During this process, the implant's legs close and it's s-shaped back shrinks providing uniform compression while the alloy's structure transforms into a state approximately 20% stronger then 316L stainless steel. The OSSpine(TM) implant actively compresses the fusion construct compensating for any graft subsidence that may occur during healing.

BME recently announced that it had received a Notice of Allowance from the United States Patent and Trademark Office for 61 claims providing protection for their innovative OSSforce(TM) Implant Controller technology. The OSSpine(TM) implants and the OSSforce(TM) Implant Controller will be showcased by BME at the North American Spine Society (NASS) 22nd Annual Meeting being held October 23-27, 2007 in Austin, Texas.

BioMedical Enterprises, Inc. (BME) is a medical device company that addresses the changing needs in musculoskeletal medicine. BME focuses on minimally invasive orthopaedic instrumentation and implants that elicit a biologic response. BME's focus on memory metal internal fixation implants is changing the shape of orthopaedic medicine. Its specialized history of musculoskeletal research services will continue to produce unique, state of the art orthopaedic products that provide better outcomes for patients and more convenience to surgeons. For more information visit http://www.bme-tx.com.


'/>"/>
SOURCE BioMedical Enterprises, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Biomedical engineering conference invites manufacturers
2. Manufacturing partnership will move into biotech and biomedical spaces
3. Biomedical Alliance about more than stem cells
4. Doyle seeks $2.5M for biomedical alliance
5. Students will show off biomedical devices to professors and investors
6. Biomedical alliance marks first full year
7. UW Biomedical Engineering awarded $2.9 million research grant
8. Having two biomedical tech centers in Wisconsin will help the state
9. New biomedical institute aims to unite business and academia in SE Wisconsin
10. Wisconsin publicly traded biomedical companies report gains this quarter
11. Medical College receives $377K to study brain disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... ... The American Academy of Thermology (AAT) has announced that for ... Certification Qualification Course for Technicians via a two part webinar on July 30 and ... review of hardware, software, and camera setup/operations, aligns with the in-person member qualification course ...
(Date:2/9/2016)... , Feb. 9, 2016 This market ... the current and future prospects of the market in ... report include companies engaged in the manufacture of microbiology ... executive summary with a market snapshot providing the overall ... of this report. This section also provides the overall ...
(Date:2/9/2016)... LONDON , Feb. 9, 2016 /PRNewswire/ ... (PTP1B) Inhibitors-Pipeline Insights, 2016", report provides in ... their development activities around the Protein-Tyrosine Phosphatase ... the product profiles in various stages of ... Phase II, Phase III and Preregistration. Report ...
(Date:2/8/2016)... February 8, 2016 ... Limited, an innovation-driven oncology company developing next generation ... toxic, today announced that chairman emeritus of Tata ... in the company as part of the first ... existing investors Navam Capital and Aarin Capital. ...
Breaking Biology Technology:
(Date:2/4/2016)... , Feb. 4, 2016 The ... apparently one of the most popular hubs of ... MetaHIT and other huge studies of human microbiota, ... past few years, the microbiome space has literally ... biomedical research. This report focuses on biomedical ...
(Date:2/3/2016)... Feb. 3, 2016 ... of the "Emotion Detection and Recognition ... and Others), Software Tools (Facial Expression, Voice ... Users,and Regions - Global forecast to 2020" ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the ...
(Date:2/2/2016)... , Feb. 2, 2016 Technology Enhancements Accelerate ... an analysis of the digital and computed radiography markets ... , and Indonesia (TIM). ... and market size, as well as regional market drivers ... and discusses market penetration and market attractiveness, both for ...
Breaking Biology News(10 mins):